Skip to content

Effect of Inspired Oxygen Concentration on Postoperative Atelectasis After VATS Lobectomy

Effect of Inspired Oxygen Concentration on Postoperative Atelectasis in Patients Undergoing Elective Thoracoscopic Pulmonary Lobectomy Based on Perioperative Lung Protection Strategy: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07721558
Enrollment
100
Registered
2026-07-23
Start date
2026-09-01
Completion date
2027-12-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atelectasis, Postoperative Pulmonary Complications

Keywords

Inspired oxygen concentration, One-lung ventilation, Lung recruitment maneuver

Brief summary

This study aims to investigate whether using 50% FiO₂ during one-lung ventilation, compared with 100% FiO₂, reduces postoperative atelectasis in the non-dependent (healthy) lung of patients undergoing VATS pulmonary lobectomy, based on individualized PEEP titration. This is a single-center, prospective, assessor- and patient-blinded randomized controlled trial. A total of 100 patients (50 per group, including a pilot phase of 10 per group) will be enrolled and randomized 1:1 to the high-oxygen group (FiO₂=100%) and the low-oxygen group (FiO₂=50%). The primary endpoint is the percentage of atelectasis volume in the non-operated lung relative to the total non-operated lung volume, assessed by CT at 60±10 minutes after tracheal extubation.

Interventions

PROCEDURELow inspired oxygen concentration (FiO₂=50%) during one-lung ventilation

Ventilation with initial FiO₂=50% during one-lung ventilation, combined with individualized PEEP titration. Oxygen concentration is dynamically adjusted based on SpO₂; ventilation duration at each FiO₂ level and total oxygen exposure burden are recorded.

PROCEDUREHigh inspired oxygen concentration (FiO₂=100%) during one-lung ventilaion

Ventilation with FiO₂=100% throughout one-lung ventilation, combined with individualized PEEP titration (decremental PEEP titration selecting the highest PEEP corresponding to the lowest driving pressure).

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Patients are blinded pre- and postoperatively; postoperative data collectors, CT readers, and biostatisticians are blinded to allocation; only the attending anesthesiologist is unblinded due to the nature of the intervention (setting FiO₂), but does not participate in data collection or outcome assessment

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Age 18-65 years Elective thoracoscopic (VATS) pulmonary lobectomy Anticipated one-lung ventilation duration \>1 hour ASA physical status I-III

Exclusion criteria

Previous pulmonary surgery (including lobectomy, lung volume reduction surgery, or other lung resection) Pre-existing significant atelectasis (large collapse on preoperative CT) Contraindications to PEEP: intracranial hypertension, bronchopleural fistula, hypovolemic shock, right heart failure, giant bullae, pneumothorax Preoperative continuous oxygen therapy or mechanical ventilation, moderate-severe COPD BMI ≥ 30 kg/m² Ischemic cardiovascular and cerebrovascular diseases, such as myocardial infarction, ischemic stroke, and patients with coronary or cerebrovascular stents Patient refusal to participate Withdrawal Criteria / Major Protocol Deviations: Surgery changed to simple wedge resection Severe pleural adhesions (found intraoperatively) One-lung ventilation duration \< 50 minutes Intraoperative blood loss \> 500 ml Severe hypotension (MAP \< 55 mmHg despite high-dose vasopressors) Unexpected non-thoracic surgical procedure Ventilation protocol interrupted (e.g., FiO₂ exposure \< 80% of planned time in the low-oxygen group) Postoperative CT not completed or image quality unusable Subject withdrawal of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Non-operated lung atelectasis volume percentageCT scans were performed at 60 ± 10 minutes after tracheal extubation to assess the volume ratio of atelectasis in the contralateral lung.Chest CT at 60±10 minutes after tracheal extubation

Secondary

MeasureTime frameDescription
Incidence of intraoperative adverse eventsIntraoperative (from induction to emergence)Incidence of intraoperative adverse events including hypoxemia (SpO₂ \< 90%), hypotension (MAP decreased \> 20% from baseline for \> 3 minutes), new-onset arrhythmia, and cerebral oxygen desaturation (rSO₂ \< 50% or \> 20% decrease from baseline)
Oxidative stress marker (MDA)1 hour after one lung ventilationArterial blood malondialdehyde (MDA) level at 1 hour after one lung ventilation
Postoperative renal function (serum creatinine and eGFR)Postoperative days 1 and 3Serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) to assess postoperative acute kidney injury
Intraoperative oxygen saturationIntraoperative (during one lung ventilation)Oxygen saturation (pulse oxygen)
Incidence of postoperative pulmonary complicationsPostoperative days 1-3PPC defined as Melbourne Postoperative Pulmonary Complication score ≥4
QoR-15 quality of recovery scorePostoperative days 1-315-item Quality of Recovery questionnaire score
Oxygen concentration exposure burdenIntraoperative (during one lung ventilation)Sum of FiO₂ × time; incidence and frequency of FiO₂ increase
Arterial blood gas analysis (oxygenation index)Multiple time points: (1) preoperative preparation room; (2) 5 minutes after two-lung ventilation at induction; (3) 5 minutes after one-lung ventilation start; (4) 1 hour after one-lung ventilation; (5) 10 minutes after tracheal extubationPaO₂/FiO₂ ratio, PaO₂, PaCO₂, and pH at five predefined time points

Countries

China

Contacts

CONTACTYi Feng, Ph.D
doc_yifeng@163.com010-88325590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026